China Biologic Products continued on its acquisitive path by announcing its intention to purchase a 35% stake in Xi'an Huitian Blood Products Co., Ltd. Both companies manufacture plasma-based pharmaceuticals. China Biologic will pay 44 million RMB ($6.4 million) for the purchase of Huitian. Two weeks ago, China Biologic announced a $28.5 million deal under which it will acquire a 50% controlling interest in Qianfeng Biological Products of Guizhou Province, also a plasma-based pharma. More details...
Stock Symbol: (OTCBB: CBPO)